StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ:TTNP opened at $3.52 on Friday. The firm’s 50 day simple moving average is $3.82 and its 200-day simple moving average is $5.09. Titan Pharmaceuticals has a one year low of $3.12 and a one year high of $14.80.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.